| 產(chǎn)品名稱 |
B505 |
| 商品貨號 |
B210932 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma:lymphoblast B lymphocyte; somatic cell hybri |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain |
Strain: BALB/c (B cell); BALB/c (myeloma) |
| Applications |
The B505 antibody specifically binds to hLH beta core fragment without cross-reacting with hLH, hLH beta or human chorionic gonadotropin (hCG) beta core fragment [U.S. Pat. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Animals were immunized with human luteinizing hormone (hLH) beta core fragment isolated from human pituitary extracts. Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells. The B505 antibody specifically binds to hLH beta core fragment without cross-reacting with hLH, hLH beta or human chorionic gonadotropin (hCG) beta core fragment [U.S. Pat. 5,976,876]. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human luteinizing hormone (hLH) beta core fragment |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human luteinizing hormone (hLH) beta core fragment |
| Comments |
Animals were immunized with human luteinizing hormone (hLH) beta core fragment isolated from human pituitary extracts. Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells. The B505 antibody specifically binds to hLH beta core fragment without cross-reacting with hLH, hLH beta or human chorionic gonadotropin (hCG) beta core fragment [U.S. Pat. 5,976,876]. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
| Subculturing |
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 X 10(6) cells/ml. Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 X 10(6) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype |
mouse IgG1 kappa |
| Name of Depositor |
Trustees of Columbia University |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Canfield RE, et al. Antibodies specific for hLH beta core fragment. US Patent 5,976,876 dated Nov 2 1999
Birkin S, et al. Determination of the amount of hLH.beta. core fragment in a sample from a subject and uses thereof. US Patent 6,521,416 dated Feb 18 2003
|
